The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?

Sep 2, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Noopur Raje, Massachusetts General Hospital, Boston, US, about chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM).

Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?

Recent data from the currently ongoing KarMMa trial has shown a progression-free survival (PFS) of only 10.5 months for all participants. Patients that achieved a stringent complete response reached a PFS of approximately 20 months.

Therefore, we asked, Why do we not see curative CAR T-cell therapy in MM (compared to diffuse large B-cell lymphoma [DLBCL] and acute lymphoblastic leukemia [ALL])?